Corrections to “Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression” † † Presented in part at the 31st (10–14 December 2008), and at the 33rd (8–12 December 2010) Annual San Antonio Breast Cancer Symposium San Antonio, TX, and at the 44th Annual Meeting of the American Society of Clinical Oncology (30 May–03 June 2008), Chicago, IL, USA.
Titel:
Corrections to “Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression” † † Presented in part at the 31st (10–14 December 2008), and at the 33rd (8–12 December 2010) Annual San Antonio Breast Cancer Symposium San Antonio, TX, and at the 44th Annual Meeting of the American Society of Clinical Oncology (30 May–03 June 2008), Chicago, IL, USA.
Auteur:
Nitz, U. Gluz, O. Huober, J. Kreipe, H.H. Kates, R.E. Hartmann, A. Erber, R. Moustafa, Z. Scholz, M. Lisboa, B. Mohrmann, S. Möbus, V. Augustin, D. Hoffmann, G. Weiss, E. Böhmer, S. Kreienberg, R. Du Bois, A. Sattler, D. Thomssen, C. Kiechle, M. Jänicke, F. Wallwiener, D. Harbeck, N. Kuhn, W.